Heartflow (NASDAQ:HTFL) Announces Earnings Results, Misses Estimates By $0.08 EPS

Heartflow (NASDAQ:HTFL) issued its earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.08), Zacks reports.

Heartflow Stock Up 4.6%

Shares of NASDAQ HTFL traded up $1.57 during trading on Wednesday, hitting $35.74. 594,401 shares of the company traded hands, compared to its average volume of 409,220. Heartflow has a 1 year low of $26.56 and a 1 year high of $41.22. The stock has a 50-day moving average of $34.64.

Wall Street Analyst Weigh In

HTFL has been the topic of a number of recent analyst reports. Stifel Nicolaus assumed coverage on Heartflow in a report on Tuesday, September 2nd. They issued a “buy” rating and a $35.00 price objective on the stock. Canaccord Genuity Group upped their target price on shares of Heartflow from $35.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 22nd. Wall Street Zen upgraded shares of Heartflow to a “hold” rating in a research note on Saturday, August 16th. Piper Sandler initiated coverage on Heartflow in a report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, Morgan Stanley started coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $36.60.

Hedge Funds Weigh In On Heartflow

An institutional investor recently bought a new position in Heartflow stock. Vanguard Group Inc. bought a new position in Heartflow, Inc. (NASDAQ:HTFL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,451,913 shares of the company’s stock, valued at approximately $48,871,000. Vanguard Group Inc. owned about 1.74% of Heartflow as of its most recent filing with the Securities and Exchange Commission.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.